Targeting the modulation of neural circuitry for the treatment of anxiety disorders

Pharmacological Reviews

Volumn 66, Issue 4, 2014, Pages 1002-1032

  Farb, David H ^a   Ratner, Marcia H ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; BENZODIAZEPINE DERIVATIVE; BIOLOGICAL MARKER; HISTONE DEACETYLASE INHIBITOR; NATURAL PRODUCT; NEUROSTEROID; SEROTONIN RECEPTOR; ANXIOLYTIC AGENT;

ANXIETY DISORDER; BRAIN ELECTROPHYSIOLOGY; CONNECTOME; DOPAMINERGIC TRANSMISSION; EPIGENETICS; FUNCTIONAL MAGNETIC RESONANCE IMAGING; FUNCTIONAL NEUROIMAGING; GABAERGIC TRANSMISSION; HUMAN; NEUROIMAGING; NEUROMODULATION; NONHUMAN; NORADRENERGIC TRANSMISSION; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OPTOGENETICS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; REVIEW; SEROTONERGIC TRANSMISSION; SEROTONINERGIC TRANSMISSION; SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY; TRANQUILIZING ACTIVITY; ANIMAL; ANXIETY DISORDERS; BRAIN; DRUG DESIGN; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOPHYSIOLOGY;

ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY DISORDERS; BRAIN; DRUG DESIGN; HUMANS; MOLECULAR TARGETED THERAPY; RECEPTORS, GABA-A;

EID: 84920399406     PISSN: 00316997     EISSN: 15210081     Source Type: Journal    
DOI: 10.1124/pr.114.009126     Document Type: Review

References (346)

1. Ahmadi H, Nasehi M, Rostami P, and Zarrindast MR (2013) Involvement of the nucleus accumbens shell dopaminergic system in prelimbic NMDA-induced anxiolytic-like behaviors. Neuropharmacology 71:112-123.
2. Alger BE and Nicoll RA (1982) Pharmacological evidence for two kinds of GABA receptor on rat hippocampal pyramidal cells studied in vitro. J Physiol 328:125-141.
3. Alkhatib AH, Dvorkin-Gheva A, and Szechtman H (2013) Quinpirole and 8-OH-DPAT induce compulsive checking behavior in male rats by acting on different functional parts of an OCD neurocircuit. Behav Pharmacol 24:65-73.
4. Allgulander C, Bandelow B, Hollander E, Montgomery SA, Nutt DJ, Okasha A, Pollack MH, Stein DJ, Swinson RP, and World Council of Anxiety (2003) WCA recommendations for the long-term treatment of generalized anxiety disorder. CNS Spectr 8 (Suppl 1)53-61.
5. American Psychiatric Association (2013) Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), American Psychiatric Association, Washington, DC.
6. Amin J, Brooks-Kayal A, and Weiss DS (1997) Two tyrosine residues on the alpha subunit are crucial for benzodiazepine binding and allosteric modulation of gamma-aminobutyric acidA receptors. Mol Pharmacol 51:833-841.
7. Amin J and Weiss DS (1993) GABAA receptor needs two homologous domains of the beta-subunit for activation by GABA but not by pentobarbital. Nature 366:565-569.
8. Ashton H and Young AH (2003) GABA-ergic drugs: exit stage left, enter stage right. J Psychopharmacol 17:174-178.
9. Atack JR (2003) Anxioselective compounds acting at the GABA(A) receptor benzodiazepine binding site. Curr Drug Targets CNS Neurol Disord 2:213-232.
10. Atack JR, Hallett DJ, Tye S, Wafford KA, Ryan C, Sanabria-Bohórquez SM, Eng WS, Gibson RE, Burns HD, Dawson GR, et al. (2011a) Preclinical and clinical pharmacology of TPA023B, a GABAA receptor α2/α3 subtype-selective partial agonist. J Psychopharmacol 25:329-344.
11. Atack JR, Pike A, Marshall G, Stanley J, Lincoln R, Cook SM, Lewis RT, Blackaby WP, Goodacre SC, McKernan RM, et al. (2006a) The in vivo properties of pagoclone in rat are most likely mediated by 5′-hydroxy pagoclone. Neuropharmacology 50:677-689.
12. Atack JR, Wafford KA, Street LJ, Dawson GR, Tye S, Van Laere K, Bormans G, Sanabria-Bohórquez SM, De Lepeleire I, de Hoon JN, et al. (2011b) MRK-409 (MK-0343), a GABAA receptor subtype-selective partial agonist, is a non-sedating anxiolytic in preclinical species but causes sedation in humans. J Psychopharmacol 25:314-328.
13. Atack JR, Wafford KA, Tye SJ, Cook SM, Sohal B, Pike A, Sur C, Melillo D, Bristow L, Bromidge F, et al. (2006b) TPA023 [7-(1,1-dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine], an agonist selective for alpha2- and alpha3-containing GABAA receptors, is a nonsedating anxiolytic in rodents and primates. J Pharmacol Exp Ther 316:410-422.
14. Agustín-Pavón C, Braesicke K, Shiba Y, Santangelo AM, Mikheenko Y, Cockroft G, Asma F, Clarke H, Man MS, and Roberts AC (2012) Lesions of ventrolateral prefrontal or anterior orbitofrontal cortex in primates heighten negative emotion. Biol Psychiatry 72:266-272.
15. Aupperle RL, Hale LR, Chambers RJ, Cain SE, Barth FX, Sharp SC, Denney DR, and Savage CR (2009) An fMRI study examining effects of acute D-cycloserine during symptom provocation in spider phobia. CNS Spectr 14:556-571.
16. Baldwin D, Woods R, Lawson R, and Taylor D (2011) Efficacy of drug treatments for generalised anxiety disorder: systematic review and meta-analysis. BMJ 342:d1199.
17. Ballenger JC, McDonald S, Noyes R, Rickels K, Sussman N, Woods S, Patin J, and Singer J (1991) The first double-blind, placebo-controlled trial of a partial benzodiazepine agonist abecarnil (ZK 112-119) in generalized anxiety disorder. Psychopharmacol Bull 27:171-179.
18. Ballenger JC, McDonald S, Noyes R Jr., Rickels K, Woods SW, Patin J, Lydiard B, Garvey M, Cook B, Goodard AW, et al. (1992) The first double-blind, placebo-controlled trial of a partial benzodiazepine agonist, abecarnil (ZK 112-119), in generalized anxiety disorder. Adv Biochem Psychopharmacol 47:431-447.
19. Barbaccia ML, Roscetti G, Trabucchi M, Mostallino MC, Concas A, Purdy RH, and Biggio G (1996) Time-dependent changes in rat brain neuroactive steroid concentrations and GABAA receptor function after acute stress. Neuroendocrinology 63:166-172.
20. Barkus C, McHugh SB, Sprengel R, Seeburg PH, Rawlins JN, and Bannerman DM (2010) Hippocampal NMDA receptors and anxiety: at the interface between cognition and emotion. Eur J Pharmacol 626:49-56.
21. Barnard EA, Skolnick P, Olsen RW, Mohler H, Sieghart W, Biggio G, Braestrup C, Bateson AN, and Langer SZ (1998) International Union of Pharmacology. XV. Subtypes of gamma-aminobutyric acidA receptors: Classification on the basis of subunit structure and receptor function. Pharmacol Rev 50:291-313.
22. Bateson A (2003) Pagoclone Indevus. Curr Opin Investig Drugs 4:91-95.
23. Battista MA, Hierholzer R, Khouzam HR, Barlow A, and O’Toole S (2007) Pilot trial of memantine in the treatment of posttraumatic stress disorder. Psychiatry 70:167-174.
24. Baur R and Sigel E (2003) On high- and low-affinity agonist sites in GABAA receptors. J Neurochem 87:325-332.
25. Ben-Ari Y (2002) Excitatory actions of gaba during development: the nature of the nurture. Nat Rev Neurosci 3:728-739.
26. Benke D, Honer M, Michel C, and Mohler H (1996) GABAA receptor subtypes differentiated by their gamma-subunit variants: prevalence, pharmacology and subunit architecture. Neuropharmacology 35:1413-1423.
27. Bennett JA, Moioffer M, Stanton SP, Dwight M, and Keck PE Jr. (1998) A risk-benefit assessment of pharmacological treatments for panic disorder. Drug Saf 18:419-430.
28. Sibley D, Kuhar M, Hanin I, and Skolnick P, Berezhnoy D, Gravielle MC, and Farb DH (2007) Pharmacology of the GABA-A receptor, in Handbook of Contemporary Neuropharmacology (Sibley D, Kuhar M, Hanin I, and Skolnick P eds), pp 465-568, John Wiley & Sons, Inc., Hoboken, NJ.
29. Berton F, Francesconi WG, Madamba SG, Zieglgänsberger W, and Siggins GR (1998) Acamprosate enhances N-methyl-D-apartate receptor-mediated neurotransmission but inhibits presynaptic GABA(B) receptors in nucleus accumbens neurons. Alcohol Clin Exp Res 22:183-191.
30. Blanco C, Schneier FR, Schmidt A, Blanco-Jerez CR, Marshall RD, Sánchez-Lacay A, and Liebowitz MR (2003) Pharmacological treatment of social anxiety disorder: a meta-analysis. Depress Anxiety 18:29-40.
31. Boileau AJ and Czajkowski C (1999) Identification of transduction elements for benzodiazepine modulation of the GABA(A) receptor: three residues are required for allosteric coupling. J Neurosci 19:10213-10220.
32. Borden LA, Czajkowski C, Chan CY, and Farb DH (1984) Benzodiazepine receptor synthesis and degradation by neurons in culture. Science 226:857-860.
33. Borden LA and Farb DH (1988) Mechanism of gamma-aminobutyric acid/benzodiazepine receptor turnover in neuronal cells: evidence for nonlysosomal degradation. Mol Pharmacol 34:354-362.
34. Braestrup C and Nielsen M (1981) [3H]Propyl beta-carboline-3-carboxylate as a selective radioligand for the BZ1 benzodiazepine receptor subclass. J Neurochem 37:333-341.
35. Braestrup C and Squires RF (1977) Specific benzodiazepine receptors in rat brain characterized by high-affinity (3H)diazepam binding. Proc Natl Acad Sci USA 74:3805-3809.
36. Braestrup C and Squires RF (1978) Pharmacological characterization of benzodiazepine receptors in the brain. Eur J Pharmacol 48:263-270.
37. Bremner JD, Innis RB, White T, Fujita M, Silbersweig D, Goddard AW, Staib L, Stern E, Cappiello A, Woods S, et al. (2000) SPECT [I-123]iomazenil measurement of the benzodiazepine receptor in panic disorder. Biol Psychiatry 47:96-106.
38. Brooks-Kayal AR and Pritchett DB (1993) Developmental changes in human gamma-aminobutyric acidA receptor subunit composition. Ann Neurol 34:687-693.
39. Brot MD, Akwa Y, Purdy RH, Koob GF, and Britton KT (1997) The anxiolytic-like effects of the neurosteroid allopregnanolone: interactions with GABA(A) receptors. Eur J Pharmacol 325:1-7.
40. Brouillet E, Chavoix C, Bottlaender M, Khalili-Varasteh M, Hantraye P, Fournier D, Dodd RH, and Mazière M (1991) In vivo bidirectional modulatory effect of benzodiazepine receptor ligands on GABAergic transmission evaluated by positron emission tomography in non-human primates. Brain Res 557:167-176.
41. Buhr A and Sigel E (1997) A point mutation in the gamma2 subunit of gamma-aminobutyric acid type A receptors results in altered benzodiazepine binding site specificity. Proc Natl Acad Sci USA 94:8824-8829.
42. Busto U, Kaplan HL, Zawertailo L, and Sellers EM (1994) Pharmacologic effects and abuse liability of bretazenil, diazepam, and alprazolam in humans. Clin Pharmacol Ther 55:451-463.
43. Calogero AE, Palumbo MA, Bosboom AM, Burrello N, Ferrara E, Palumbo G, Petraglia F, and D’Agata R (1998) The neuroactive steroid allopregnanolone suppresses hypothalamic gonadotropin-releasing hormone release through a mechanism mediated by the gamma-aminobutyric acidA receptor. J Endocrinol 158:121-125.
44. Carlson JN, Haskew R, Wacker J, Maisonneuve IM, Glick SD, and Jerussi TP (2001) Sedative and anxiolytic effects of zopiclone’s enantiomers and metabolite. Eur J Pharmacol 415:181-189.
45. Carter RB, Wood PL, Wieland S, Hawkinson JE, Belelli D, Lambert JJ, White HS, Wolf HH, Mirsadeghi S, Tahir SH, et al. (1997) Characterization of the anticonvulsant properties of ganaxolone (CCD 1042; 3α-hydroxy-3β-methyl-5α-pregnan-20-one), a selective, high-affinity, steroid modulator of the γ-aminobutyric acid(A) receptor. J Pharmacol Exp Ther 280:1284-1295.
46. Casalotti SO, Stephenson FA, and Barnard EA (1986) Separate subunits for agonist and benzodiazepine binding in the gamma-aminobutyric acidA receptor oligomer. J Biol Chem 261:15013-15016.
47. Cassano P, Soares CN, Cohen LS, Lyster AK, and Fava M (2004) Sex- and age-related differences in major depressive disorder with comorbid anxiety treated with fluoxetine. Arch Women Ment Health 7:167-171.
48. Casu MA, Sanna A, Spada GP, Falzoi M, Mongeau R, and Pani L (2007) Effects of acute and chronic valproate treatments on p-CREB levels in the rat amygdala and nucleus accumbens. Brain Res 1141:15-24.
49. Cha J, Greenberg T, Carlson JM, Dedora DJ, Hajcak G, and Mujica-Parodi LR (2014) Circuit-wide structural and functional measures predict ventromedial prefrontal cortex fear generalization: implications for generalized anxiety disorder. J Neurosci 34:4043-4053.
50. Charalampopoulos I, Remboutsika E, Margioris AN, and Gravanis A (2008) Neurosteroids as modulators of neurogenesis and neuronal survival. Trends Endocrinol Metab 19:300-307.
51. Chan CY and Farb DH (1985) Modulation of neurotransmitter action: control of the gamma-aminobutyric acid response through the benzodiazepine receptor. J Neurosci 5:2365-2373.
52. Chang Y, Wang R, Barot S, and Weiss DS (1996) Stoichiometry of a recombinant GABAA receptor. J Neurosci 16:5415-5424.
53. Chee SS, Menard JL, and Dringenberg HC (2014) Behavioral anxiolysis without reduction of hippocampal theta frequency after histamine application in the lateral septum of rats. Hippocampus 24:615-627.
54. Chiu TH and Rosenberg HC (1979) GABA receptor-mediated modulation of 3H-diazepam binding in rat cortex. Eur J Pharmacol 56:337-345.
55. Choi DW, Farb DH, and Fischbach GD (1977) Chlordiazepoxide selectively augments GABA action in spinal cord cell cultures. Nature 269:342-344.
56. Cole JC and Rodgers RJ (1993) An ethological analysis of the effects of chlordiazepoxide and bretazenil (Ro 16-6028) in the murine elevated plus-maze. Behav Pharmacol 4:573-580.
57. Collins I, Moyes C, Davey WB, Rowley M, Bromidge FA, Quirk K, Atack JR, McKernan RM, Thompson SA, Wafford K, et al. (2002) 3-Heteroaryl-2-pyridones: benzodiazepine site ligands with functional delectivity for alpha 2/alpha 3-subtypes of human GABA(A) receptor-ion channels. J Med Chem 45:1887-1900.
58. Covey DF, Nathan D, Kalkbrenner M, Nilsson KR, Hu Y, Zorumski CF, and Evers AS (2000) Enantioselectivity of pregnanolone-induced gamma-aminobutyric acid(A) receptor modulation and anesthesia. J Pharmacol Exp Ther 293:1009-1016.
59. Czajkowski C and Farb DH (1986) Transmembrane topology and subcellular distribution of the benzodiazepine receptor. J Neurosci 6:2857-2863.
60. Czéh B, Michaelis T, Watanabe T, Frahm J, de Biurrun G, van Kampen M, Bartolomucci A, and Fuchs E (2001) Stress-induced changes in cerebral metabolites, hippocampal volume, and cell proliferation are prevented by antidepressant treatment with tianeptine. Proc Natl Acad Sci USA 98:12796-12801.
61. Davidson JR (2003) Pharmacotherapy of social phobia. Acta Psychiatr Scand Suppl 417:65-71.
62. Davis M and Myers KM (2002) The role of glutamate and gamma-aminobutyric acid in fear extinction: clinical implications for exposure therapy. Biol Psychiatry 52:998-1007.
63. de Wit H, Vicini L, Haig GM, Hunt T, and Feltner D (2006) Evaluation of the abuse potential of pagoclone, a partial GABAA agonist. J Clin Psychopharmacol 26:268-273.
64. Gad SDesbiens S and Farb DH (2012) Current needs for new therapeutic agents and discovery strategies - a systems pharmacology approach, in Development of Therapeutic Agents (Gad S ed) vol 416, pp 1-24, John Wiley & Sons, Inc., Hoboken, NJ.
65. Dias R, Sheppard WF, Fradley RL, Garrett EM, Stanley JL, Tye SJ, Goodacre S, Lincoln RJ, Cook SM, Conley R, et al. (2005) Evidence for a significant role of alpha 3-containing GABAA receptors in mediating the anxiolytic effects of benzodiazepines. J Neurosci 25:10682-10688.
66. Difede J, Cukor J, Wyka K, Olden M, Hoffman H, Lee FS, and Altemus M (2014) D-cycloserine augmentation of exposure therapy for post-traumatic stress disorder: a pilot randomized clinical trial. Neuropsychopharmacology 39:1052-1058.
67. Doehrmann O, Ghosh SS, Polli FE, Reynolds GO, Horn F, Keshavan A, Triantafyllou C, Saygin ZM, Whitfield-Gabrieli S, Hofmann SG, et al. (2013) Predicting treatment response in social anxiety disorder from functional magnetic resonance imaging. JAMA Psychiatry 70:87-97.
68. Drover DR (2004) Comparative pharmacokinetics and pharmacodynamics of short-acting hypnosedatives: zaleplon, zolpidem and zopiclone. Clin Pharmacokinet 43:227-238.
69. Duncan GE, Breese GR, Criswell HE, McCown TJ, Herbert JS, Devaud LL, and Morrow AL (1995) Distribution of [3H]zolpidem binding sites in relation to messenger RNA encoding the alpha 1, beta 2 and gamma 2 subunits of GABAA receptors in rat brain. Neuroscience 64:1113-1128.
70. Dunn JD (1987) Plasma corticosterone responses to electrical stimulation of the bed nucleus of the stria terminalis. Brain Res 407:327-331.
71. Engels AS, Heller W, Mohanty A, Herrington JD, Banich MT, Webb AG, and Miller GA (2007) Specificity of regional brain activity in anxiety types during emotion processing. Psychophysiology 44:352-363.
72. Etkin A and Wager TD (2007) Functional neuroimaging of anxiety: a meta-analysis of emotional processing in PTSD, social anxiety disorder, and specific phobia. Am J Psychiatry 164:1476-1488.
73. Facklam M, Schoch P, Bonetti EP, Jenck F, Martin JR, Moreau JL, and Haefely WE (1992a) Relationship between benzodiazepine receptor occupancy and functional effects in vivo of four ligands of differing intrinsic efficacies. J Pharmacol Exp Ther 261:1113-1121.
74. Facklam M, Schoch P, and Haefely WE (1992b) Relationship between benzodiazepine receptor occupancy and potentiation of gamma-aminobutyric acid-stimulated chloride flux in vitro of four ligands of differing intrinsic efficacies. J Pharmacol Exp Ther 261:1106-1112.
75. Falls WA, Miserendino MJ, and Davis M (1992) Extinction of fear-potentiated startle: blockade by infusion of an NMDA antagonist into the amygdala. J Neurosci 12:854-863.
76. Farb DH, Borden LA, Chan CY, Czajkowski CM, Gibbs TT, and Schiller GD (1984) Modulation of neuronal function through benzodiazepine receptors: biochemical and electrophysiological studies of neurons in primary monolayer cell culture. Ann N Y Acad Sci 435:1-31.
77. Faria V, Appel L, Åhs F, Linnman C, Pissiota A, Frans Ö, Bani M, Bettica P, Pich EM, Jacobsson E, et al. (2012) Amygdala subregions tied to SSRI and placebo response in patients with social anxiety disorder. Neuropsychopharmacology 37:2222-2232.
78. Farkas RH, Unger EF, and Temple R (2013) Zolpidem and driving impairment—identifying persons at risk. N Engl J Med 369:689-691.
79. Felix-Ortiz AC, Beyeler A, Seo C, Leppla CA, Wildes CP, and Tye KM (2013) BLA to vHPC inputs modulate anxiety-related behaviors. Neuron 79:658-664.
80. Fernandes GA, Perks P, Cox NK, Lightman SL, Ingram CD, and Shanks N (2002) Habituation and cross-sensitization of stress-induced hypothalamic-pituitary-adrenal activity: effect of lesions in the paraventricular nucleus of the thalamus or bed nuclei of the stria terminalis. J Neuroendocrinol 14:593-602.
81. Ferrero P, Guidotti A, and Costa E (1984) Increase in the Bmax of gamma-aminobutyric acid-A recognition sites in brain regions of mice receiving diazepam. Proc Natl Acad Sci USA 81:2247-2251.
82. Fisher PM, Meltzer CC, Ziolko SK, Price JC, Moses-Kolko EL, Berga SL, and Hariri AR (2006) Capacity for 5-HT1A-mediated autoregulation predicts amygdala reactivity. Nat Neurosci 9:1362-1363.
83. Fleck MW (2002) Molecular actions of (S)-desmethylzopiclone (SEP-174559), an anxiolytic metabolite of zopiclone. J Pharmacol Exp Ther 302:612-618.
84. Fluoxetine (2013) Prescribing information. Eli Lilly and Company, Indianapolis, IN.
85. Follesa P, Mancuso L, Biggio F, Cagetti E, Franco M, Trapani G, and Biggio G (2002) Changes in GABA(A) receptor gene expression induced by withdrawal of, but not by long-term exposure to, zaleplon or zolpidem. Neuropharmacology 42:191-198.
86. Gallager DW and Tallman JF (1983) Consequences of benzodiazepine receptor occupancy. Neuropharmacology 22:1493-1498.
87. Gasior M, Carter RB, and Witkin JM (1999) Neuroactive steroids: potential therapeutic use in neurological and psychiatric disorders. Trends Pharmacol Sci 20:107-112.
88. Gavioli EC, Canteras NS, and De Lima TC (1999) Anxiogenic-like effect induced by substance P injected into the lateral septal nucleus. Neuroreport 10:3399-3403.
89. Gelernter J, Page GP, Stein MB, and Woods SW (2004) Genome-wide linkage scan for loci predisposing to social phobia: evidence for a chromosome 16 risk locus. Am J Psychiatry 161:59-66.
90. Geuze E, van Berckel BN, Lammertsma AA, Boellaard R, de Kloet CS, Vermetten E, and Westenberg HG (2008) Reduced GABAA benzodiazepine receptor binding in veterans with post-traumatic stress disorder. Mol Psychiatry 13:74-83, 3
91. Ghiani CA, Serra M, Motzo C, Giusti P, Cuccheddu T, Porceddu ML, and Biggio G (1994) Chronic administration of an anticonvulsant dose of imidazenil fails to induce tolerance of GABAA receptor function in mice. Eur J Pharmacol 254:299-302.
92. Giménez M, Ortiz H, Soriano-Mas C, López-Solà M, Farré M, Deus J, Martín-Santos R, Fernandes S, Fina P, Bani M, et al. (2014) Functional effects of chronic paroxetine versus placebo on the fear, stress and anxiety brain circuit in Social Anxiety Disorder: initial validation of an imaging protocol for drug discovery. Eur Neuropsychopharmacol 24:105-116.
93. Gïrdler SS, Straneva PA, Light KC, Pedersen CA, and Morrow AL (2001) Allopregnanolone levels and reactivity to mental stress in premenstrual dysphoric disorder. Biol Psychiatry 49:788-797.
94. Goddard AW, Mason GF, Almai A, Rothman DL, Behar KL, Petroff OA, Charney DS, and Krystal JH (2001) Reductions in occipital cortex GABA levels in panic disorder detected with 1h-magnetic resonance spectroscopy. Arch Gen Psychiatry 58:556-561.
95. Goddard AW, Mason GF, Appel M, Rothman DL, Gueorguieva R, Behar KL, and Krystal JH (2004) Impaired GABA neuronal response to acute benzodiazepine administration in panic disorder. Am J Psychiatry 161:2186-2193.
96. Goutman JD, Waxemberg MD, Doñate-Oliver F, Pomata PE, and Calvo DJ (2003) Flavonoid modulation of ionic currents mediated by GABA(A) and GABA(C) receptors. Eur J Pharmacol 461:79-87.
97. Grabenstatter HL, Russek SJ, and Brooks-Kayal AR (2012) Molecular pathways controlling inhibitory receptor expression. Epilepsia 53 (Suppl 9):71-78.
98. Graeff FG and Zangrossi H Jr. (2010) The dual role of serotonin in defense and the mode of action of antidepressants on generalized anxiety and panic disorders. Cent Nerv Syst Agents Med Chem 10:207-217.
99. Graham D, Faure C, Besnard F, and Langer SZ (1996) Pharmacological profile of benzodiazepine site ligands with recombinant GABAA receptor subtypes. Eur Neuropsychopharmacol 6:119-125.
100. Gram L (1988) Experimental studies and controlled clinical testing of valproate and vigabatrin. Acta Neurol Scand 78:241-270.
101. Sibley D, Kuhar M, Hanin I, and Skolnick P, Gray JA and Roth BL (2007) Serotonin systems, in Handbook of Contemporary Neuropharmacology (Sibley D, Kuhar M, Hanin I, and Skolnick P eds), pp 257-298, John Wiley & Sons, Inc., Hoboken, NJ.
102. Greenberg T, Carlson JM, Cha J, Hajcak G, and Mujica-Parodi LR (2013) Ventromedial prefrontal cortex reactivity is altered in generalized anxiety disorder during fear generalization. Depress Anxiety 30:242-250.
103. Griebel G, Perrault G, Simiand J, Cohen C, Granger P, Decobert M, Françon D, Avenet P, Depoortere H, Tan S, et al. (2001) SL651498: an anxioselective compound with functional selectivity for alpha2- and alpha3-containing gamma-aminobutyric acid(A) (GABA(A)) receptors. J Pharmacol Exp Ther 298:753-768.
104. Griffin LD and Mellon SH (1999) Selective serotonin reuptake inhibitors directly alter activity of neurosteroidogenic enzymes. Proc Natl Acad Sci USA 96:13512-13517.
105. Gulledge AT and Stuart GJ (2003) Excitatory actions of GABA in the cortex. Neuron 37:299-309.
106. Günther U, Benson J, Benke D, Fritschy JM, Reyes G, Knoflach F, Crestani F, Aguzzi A, Arigoni M, Lang Y, et al. (1995) Benzodiazepine-insensitive mice generated by targeted disruption of the gamma 2 subunit gene of gamma-aminobutyric acid type A receptors. Proc Natl Acad Sci USA 92:7749-7753.
107. Guo JD, Hammack SE, Hazra R, Levita L, and Rainnie DG (2009) Bi-directional modulation of bed nucleus of stria terminalis neurons by 5-HT: molecular expression and functional properties of excitatory 5-HT receptor subtypes. Neuroscience 164:1776-1793.
108. Häberlein H, Tschiersch KP, and Schäfer HL (1994) Flavonoids from Leptospermum scoparium with affinity to the benzodiazepine receptor characterized by structure activity relationships and in vivo studies of a plant extract. Pharmazie 49:912-922.
109. Hadingham KL, Garrett EM, Wafford KA, Bain C, Heavens RP, Sirinathsinghji DJ, and Whiting PJ (1996) Cloning of cDNAs encoding the human γ-aminobutyric acid type A receptor α 6 subunit and characterization of the pharmacology of α 6-containing receptors. Mol Pharmacol 49:253-259.
110. Hadingham KL, Wingrove P, Le Bourdelles B, Palmer KJ, Ragan CI, and Whiting PJ (1993) Cloning of cDNA sequences encoding human alpha 2 and alpha 3 gamma-aminobutyric acidA receptor subunits and characterization of the benzodiazepine pharmacology of recombinant alpha 1-, alpha 2-, alpha 3-, and alpha 5-containing human gamma-aminobutyric acidA receptors. Mol Pharmacol 43:970-975.
111. Biggio G, Concas A, and Costa EHaefely W, Facklam M, Schoch P, Martin JR, Bonetti EP, Moreau JL, Jenck F, and Richards JG (1992) Partial agonists of benzodiazepine receptors for treatment of epilepsy, sleep and anxiety disorders, in GABAergic Synaptic Transmission (Biggio G, Concas A, and Costa E eds) pp 379-394, Raven Press, NY.
112. Ham BJ, Sung Y, Kim N, Kim SJ, Kim JE, Kim DJ, Lee JY, Kim JH, Yoon SJ, and Lyoo IK (2007) Decreased GABA levels in anterior cingulate and basal ganglia in medicated subjects with panic disorder: a proton magnetic resonance spectroscopy (1H-MRS) study. Prog Neuropsychopharmacol Biol Psychiatry 31:403-411.
113. Hanson SM and Czajkowski C (2008) Structural mechanisms underlying benzodiazepine modulation of the GABA(A) receptor. J Neurosci 28:3490-3499.
114. Hariri AR, Drabant EM, Munoz KE, Kolachana BS, Mattay VS, Egan MF, and Weinberger DR (2005) A susceptibility gene for affective disorders and the response of the human amygdala. Arch Gen Psychiatry 62:146-152.
115. Harmer CJ, Mackay CE, Reid CB, Cowen PJ, and Goodwin GM (2006) Antidepressant drug treatment modifies the neural processing of nonconscious threat cues. Biol Psychiatry 59:816-820.
116. Harrison NL and Simmonds MA (1984) Modulation of the GABA receptor complex by a steroid anaesthetic. Brain Res 323:287-292.
117. Hasler G, Nugent AC, Carlson PJ, Carson RE, Geraci M, and Drevets WC (2008) Altered cerebral gamma-aminobutyric acid type A-benzodiazepine receptor binding in panic disorder determined by [11C]flumazenil positron emission tomography. Arch Gen Psychiatry 65:1166-1175.
118. Hayward C and Sanborn K (2002) Puberty and the emergence of gender differences in psychopathology. J Adolesc Health 30:49-58.
119. Hazra R, Guo JD, Dabrowska J, and Rainnie DG (2012) Differential distribution of serotonin receptor subtypes in BNST(ALG) neurons: modulation by unpredictable shock stress. Neuroscience 225:9-21.
120. Heils A, Teufel A, Petri S, Stöber G, Riederer P, Bengel D, and Lesch KP (1996) Allelic variation of human serotonin transporter gene expression. J Neurochem 66:2621-2624.
121. Heinrichs SC, Leite-Morris KA, Rasmusson AM, and Kaplan GB (2013) Repeated valproate treatment facilitates fear extinction under specific stimulus conditions. Neurosci Lett 552:108-113.
122. Henke PG (1984) The bed nucleus of the stria terminalis and immobilization-stress: unit activity, escape behaviour, and gastric pathology in rats. Behav Brain Res 11:35-45.
123. Hensler JG (2006) Serotonergic modulation of the limbic system. Neurosci Biobehav Rev 30:203-214.
124. Herb A, Wisden W, Lüddens H, Puia G, Vicini S, and Seeburg PH (1992) The third γ subunit of the γ-aminobutyric acid type A receptor family. Proc Natl Acad Sci USA 89:1433-1437.
125. Heresco-Levy U, Kremer I, Javitt DC, Goichman R, Reshef A, Blanaru M, and Cohen T (2002) Pilot-controlled trial of D-cycloserine for the treatment of post-traumatic stress disorder. Int J Neuropsychopharmacol 5:301-307.
126. Herrick-Davis K, Grinde E, Harrigan TJ, and Mazurkiewicz JE (2005) Inhibition of serotonin 5-hydroxytryptamine2c receptor function through heterodimerization: receptor dimers bind two molecules of ligand and one G-protein. J Biol Chem 280:40144-40151.
127. Hertzman M, Patt IS, and Spielman LA (2009) Open-label trial of acamprosate as a treatment for anxiety. Prim Care Companion J Clin Psychiatry 11:267.
128. Hettema JM, Prescott CA, Myers JM, Neale MC, and Kendler KS (2005) The structure of genetic and environmental risk factors for anxiety disorders in men and women. Arch Gen Psychiatry 62:182-189.
129. Heydari B and Le Mellédo JM (2002) Low pregnenolone sulphate plasma concentrations in patients with generalized social phobia. Psychol Med 32:929-933.
130. Hoehn-Saric R, Schlund MW, and Wong SH (2004) Effects of citalopram on worry and brain activation in patients with generalized anxiety disorder. Psychiatry Res 131:11-21.
131. Hofmann SG, Meuret AE, Smits JA, Simon NM, Pollack MH, Eisenmenger K, Shiekh M, and Otto MW (2006) Augmentation of exposure therapy with D-cycloserine for social anxiety disorder. Arch Gen Psychiatry 63:298-304.
132. Hosie AM, Wilkins ME, da Silva HM, and Smart TG (2006) Endogenous neurosteroids regulate GABAA receptors through two discrete transmembrane sites. Nature 444:486-489.
133. Hoyer D, Hannon JP, and Martin GR (2002) Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol Biochem Behav 71:533-554.
134. Hu XZ, Lipsky RH, Zhu G, Akhtar LA, Taubman J, Greenberg BD, Xu K, Arnold PD, Richter MA, Kennedy JL, et al. (2006) Serotonin transporter promoter gain-of-function genotypes are linked to obsessive-compulsive disorder. Am J Hum Genet 78:815-826.
135. Huen MS, Hui KM, Leung JW, Sigel E, Baur R, Wong JT, and Xue H (2003) Naturally occurring 2′-hydroxyl-substituted flavonoids as high-affinity benzodiazepine site ligands. Biochem Pharmacol 66:2397-2407.
136. Hui KM, Huen MS, Wang HY, Zheng H, Sigel E, Baur R, Ren H, Li ZW, Wong JT, and Xue H (2002) Anxiolytic effect of wogonin, a benzodiazepine receptor ligand isolated from Scutellaria baicalensis Georgi. Biochem Pharmacol 64:1415-1424.
137. Hui KM, Wang XH, and Xue H (2000) Interaction of flavones from the roots of Scutellaria baicalensis with the benzodiazepine site. Planta Med 66:91-93.
138. Isenberg N, Silbersweig D, Engelien A, Emmerich S, Malavade K, Beattie B, Leon AC, and Stern E (1999) Linguistic threat activates the human amygdala. Proc Natl Acad Sci USA 96:10456-10459.
139. Jain NS, Hirani K, and Chopde CT (2005) Reversal of caffeine-induced anxiety by neurosteroid 3-alpha-hydroxy-5-alpha-pregnane-20-one in rats. Neuropharmacology 48:627-638.
140. Jardim MC, Aguiar DC, Moreira FA, and Guimarães FS (2005) Role of glutamate ionotropic and benzodiazepine receptors in the ventromedial hypothalamic nucleus on anxiety. Pharmacol Biochem Behav 82:182-189.
141. Jeon GS, Park SH, Lee KJ, Lee MS, Chun BG, and Shin KH (2006) Valproate prevents MK801-induced changes in brain-derived neurotrophic factor mRNA in the rat brain. Eur J Pharmacol 545:142-146.
142. Jornada LK, Moretti M, Valvassori SS, Ferreira CL, Padilha PT, Arent CO, Fries GR, Kapczinski F, and Quevedo J (2010) Effects of mood stabilizers on hippocampus and amygdala BDNF levels in an animal model of mania induced by ouabain. J Psychiatr Res 44:506-510.
143. Kang-Park MH, Wilson WA, and Moore SD (2004) Differential actions of diazepam and zolpidem in basolateral and central amygdala nuclei. Neuropharmacology 46:1-9.
144. Kaschka W, Feistel H, and Ebert D (1995) Reduced benzodiazepine receptor binding in panic disorders measured by iomazenil SPECT. J Psychiatr Res 29:427-434.
145. Katsnelson A (2013) Momentum grows to make ‘personalized’ medicine more ‘precise’. Nat Med 19:249.
146. Kaufmann WA, Humpel C, Alheid GF, and Marksteiner J (2003) Compartmentation of alpha 1 and alpha 2 GABA(A) receptor subunits within rat extended amygdala: implications for benzodiazepine action. Brain Res 964:91-99.
147. Kavvadias D, Sand P, Youdim KA, Qaiser MZ, Rice-Evans C, Baur R, Sigel E, Rausch WD, Riederer P, and Schreier P (2004) The flavone hispidulin, a benzodiazepine receptor ligand with positive allosteric properties, traverses the blood-brain barrier and exhibits anticonvulsive effects. Br J Pharmacol 142:811-820.
148. Kent JM and Rauch SL (2003) Neurocircuitry of anxiety disorders. Curr Psychiatry Rep 5:266-273.
149. Kerner B, Rao AR, Christensen B, Dandekar S, Yourshaw M, and Nelson SF (2013) Rare genomic variants link bipolar disorder with anxiety disorders to CREB-regulated intracellular signaling pathways. Front Psychiatry 4:154.
150. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, and Walters EE (2005a) Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 62:593-602.
151. Kessler RC, Chiu WT, Demler O, Merikangas KR, and Walters EE (2005b) Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 62:617-627.
152. Kheirbek MA, Drew LJ, Burghardt NS, Costantini DO, Tannenholz L, Ahmari SE, Zeng H, Fenton AA, and Hen R (2013) Differential control of learning and anxiety along the dorsoventral axis of the dentate gyrus. Neuron 77:955-968.
153. Khisti RT and Chopde CT (2000) Serotonergic agents modulate antidepressant-like effect of the neurosteroid 3alpha-hydroxy-5alpha-pregnan-20-one in mice. Brain Res 865:291-300.
154. Kim SW, Fowler JS, Skolnick P, Muench L, Kang Y, Shea C, Logan J, Kim D, Carter P, King P, et al. (2014) Therapeutic doses of buspirone block D3 receptors in the living primate brain. Int J Neuropsychopharmacol 17:1257-1267.
155. Kim SY, Adhikari A, Lee SY, Marshel JH, Kim CK, Mallory CS, Lo M, Pak S, Mattis J, Lim BK, et al. (2013) Diverging neural pathways assemble a behavioural state from separable features in anxiety. Nature 496:219-223.
156. Klumpers F, Heitland I, Oosting RS, Kenemans JL, and Baas JM (2012) Genetic variation in serotonin transporter function affects human fear expression indexed by fear-potentiated startle. Biol Psychol 89:277-282.
157. Knoflach F, Benke D, Wang Y, Scheurer L, Lüddens H, Hamilton BJ, Carter DB, Mohler H, and Benson JA (1996) Pharmacological modulation of the diazepam-insensitive recombinant gamma-aminobutyric acidA receptors alpha 4 beta 2 gamma 2 and alpha 6 beta 2 gamma 2. Mol Pharmacol 50:1253-1261.
158. Kobayashi K, Ikeda Y, Sakai A, Yamasaki N, Haneda E, Miyakawa T, and Suzuki H (2010) Reversal of hippocampal neuronal maturation by serotonergic antidepressants. Proc Natl Acad Sci USA 107:8434-8439.
159. Kobiella A, Reimold M, Ulshöfer DE, Ikonomidou VN, Vollmert C, Vollstädt-Klein S, Rietschel M, Reischl G, Heinz A, and Smolka MN (2011) How the serotonin transporter 5-HTTLPR polymorphism influences amygdala function: the roles of in vivo serotonin transporter expression and amygdala structure. Transl Psychiatr 1:e37.
160. Koltunowska D, Gibula-Bruzda E, and Kotlinska JH (2013) The influence of ionotropic and metabotropic glutamate receptor ligands on anxiety-like effect of amphetamine withdrawal in rats. Prog Neuropsychopharmacol Biol Psychiatry 45:242-249.
161. Kostakis E, Smith C, Jang MK, Martin SC, Richards KG, Russek SJ, Gibbs TT, and Farb DH (2013) The neuroactive steroid pregnenolone sulfate stimulates trafficking of functional N-methyl D-aspartate receptors to the cell surface via a noncanonical, G protein, and Ca2+-dependent mechanism. Mol Pharmacol 84:261-274.
162. Kotlinska J and Bochenski M (2008) The influence of various glutamate receptors antagonists on anxiety-like effect of ethanol withdrawal in a plus-maze test in rats. Eur J Pharmacol 598:57-63.
163. Kuriyama K, Honma M, Yoshiike T, and Kim Y (2013) Valproic acid but not D-cycloserine facilitates sleep-dependent offline learning of extinction and habituation of conditioned fear in humans. Neuropharmacology 64:424-431.
164. Kushner SA, Dewey SL, and Kornetsky C (1997) Gamma-vinyl GABA attenuates cocaine-induced lowering of brain stimulation reward thresholds. Psychopharmacology (Berl) 133:383-388.
165. Lambert JJ, Belelli D, Harney SC, Peters JA, and Frenguelli BG (2001) Modulation of native and recombinant GABA(A) receptors by endogenous and synthetic neuroactive steroids. Brain Res Brain Res Rev 37:68-80.
166. Lambert JJ, Belelli D, Peden DR, Vardy AW, and Peters JA (2003) Neurosteroid modulation of GABAA receptors. Prog Neurobiol 71:67-80.
167. Lavoie AM and Twyman RE (1996) Direct evidence for diazepam modulation of GABAA receptor microscopic affinity. Neuropharmacology 35:1383-1392.
168. Le Mellédo JM and Baker G (2004) Role of progesterone and other neuroactive steroids in anxiety disorders. Expert Rev Neurother 4:851-860.
169. Legerstee JS, Verhulst FC, Robbers SC, Ormel J, Oldehinkel AJ, and van Oort FV (2013) Gender-specific developmental trajectories of anxiety during adolescence: determinants and outcomes. The TRAILS study. J Can Acad Child Adolesc Psychiatry 22:26-34.
170. Leikanger E, Ingul JM, and Larsson B (2012) Sex and age-related anxiety in a community sample of Norwegian adolescents. Scand J Psychol 53:150-157.
171. Lépine JP (2002) The epidemiology of anxiety disorders: prevalence and societal costs. J Clin Psychiatry 63 (Suppl 14):4-8.
172. Lesch KP, Bengel D, Heils A, Sabol SZ, Greenberg BD, Petri S, Benjamin J, Müller CR, Hamer DH, and Murphy DL (1996) Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 274:1527-1531.
173. Levinson DF and Devinsky O (1999) Psychiatric adverse events during vigabatrin therapy. Neurology 53:1503-1511.
174. Licata SC, Platt DM, Cook JM, Sarma PV, Griebel G, and Rowlett JK (2005) Contribution of GABAA receptor subtypes to the anxiolytic-like, motor, and discriminative stimulus effects of benzodiazepines: studies with the functionally selective ligand SL651498 [6-fluoro-9-methyl-2-phenyl-4-(pyrrolidin-1-yl-carbonyl)-2,9-dihydro-1H-pyridol[3,4-b]indol-1-one]. J Pharmacol Exp Ther 313:1118-1125.
175. Liebowitz MR, Mangano RM, Bradwejn J, Asnis G, and SAD Study Group (2005) A randomized controlled trial of venlafaxine extended release in generalized social anxiety disorder. J Clin Psychiatry 66:238-247.
176. Lingford-Hughes A, Hume SP, Feeney A, Hirani E, Osman S, Cunningham VJ, Pike VW, Brooks DJ, and Nutt DJ (2002) Imaging the GABA-benzodiazepine receptor subtype containing the alpha5-subunit in vivo with [11C]Ro15 4513 positron emission tomography. J Cereb Blood Flow Metab 22:878-889.
177. Lippa A, Czobor P, Stark J, Beer B, Kostakis E, Gravielle M, Bandyopadhyay S, Russek SJ, Gibbs TT, Farb DH, et al. (2005) Selective anxiolysis produced by ocinaplon, a GABA(A) receptor modulator. Proc Natl Acad Sci USA 102:7380-7385.
178. Lippa AS, Coupet J, Greenblatt EN, Klepner CA, and Beer B (1979) A synthetic non-benzodiazepine ligand for benzodiazepine receptors: a probe for investigating neuronal substrates of anxiety. Pharmacol Biochem Behav 11:99-106.
179. Liu X, Ramirez S, Pang PT, Puryear CB, Govindarajan A, Deisseroth K, and Tonegawa S (2012) Optogenetic stimulation of a hippocampal engram activates fear memory recall. Nature 484:381-385.
180. Lo MM, Strittmatter SM, and Snyder SH (1982) Physical separation and characterization of two types of benzodiazepine receptors. Proc Natl Acad Sci USA 79:680-684.
181. Löw K, Crestani F, Keist R, Benke D, Brünig I, Benson JA, Fritschy JM, Rülicke T, Bluethmann H, Möhler H, et al. (2000) Molecular and neuronal substrate for the selective attenuation of anxiety. Science 290:131-134.
182. Lund IV, Hu Y, Raol YH, Benham RS, Faris R, Russek SJ, and Brooks-Kayal AR (2008) BDNF selectively regulates GABAA receptor transcription by activation of the JAK/STAT pathway. Sci Signal 1:ra9.
183. Macdonald RL and Barker JL (1978) Different actions of anticonvulsant and anesthetic barbiturates revealed by use of cultured mammalian neurons. Science 200:775-777.
184. Macdonald RL, Rogers CJ, and Twyman RE (1989) Kinetic properties of the GABAA receptor main conductance state of mouse spinal cord neurones in culture. J Physiol 410:479-499.
185. Majewska MD, Mienville JM, and Vicini S (1988) Neurosteroid pregnenolone sulfate antagonizes electrophysiological responses to GABA in neurons. Neurosci Lett 90:279-284.
186. Malizia AL, Cunningham VJ, Bell CJ, Liddle PF, Jones T, and Nutt DJ (1998) Decreased brain GABA(A)-benzodiazepine receptor binding in panic disorder: preliminary results from a quantitative PET study. Arch Gen Psychiatry 55:715-720.
187. Malminiemi O and Korpi ER (1989) Diazepam-insensitive [3H]Ro 15-4513 binding in intact cultured cerebellar granule cells. Eur J Pharmacol 169:53-60.
188. Mao SC, Lin HC, and Gean PW (2008) Augmentation of fear extinction by D-cycloserine is blocked by proteasome inhibitors. Neuropsychopharmacology 33:3085-3095.
189. Masneuf S, Lowery-Gionta E, Colacicco G, Pleil KE, Li C, Crowley N, Flynn S, Holmes A, and Kash T (2014) Glutamatergic mechanisms associated with stress-induced amygdala excitability and anxiety-related behavior. Neuropsychopharmacology 85:190-197.
190. Mathers DA (1985) Spontaneous and GABA-induced single channel currents in cultured murine spinal cord neurons. Can J Physiol Pharmacol 63:1228-1233.
191. Mathew SJ, Amiel JM, Coplan JD, Fitterling HA, Sackeim HA, and Gorman JM (2005) Open-label trial of riluzole in generalized anxiety disorder. Am J Psychiatry 162:2379-2381.
192. Mato S, Vidal R, Castro E, Díaz A, Pazos A, and Valdizán EM (2010) Long-term fluoxetine treatment modulates cannabinoid type 1 receptor-mediated inhibition of adenylyl cyclase in the rat prefrontal cortex through 5-hydroxytryptamine 1A receptor-dependent mechanisms. Mol Pharmacol 77:424-434.
193. Matsumoto K, Uzunova V, Pinna G, Taki K, Uzunov DP, Watanabe H, Mienville JM, Guidotti A, and Costa E (1999) Permissive role of brain allopregnanolone content in the regulation of pentobarbital-induced righting reflex loss. Neuropharmacology 38:955-963.
194. McGaugh JL (2000) Memory—a century of consolidation. Science 287:248-251.
195. McGregor IS, Hargreaves GA, Apfelbach R, and Hunt GE (2004) Neural correlates of cat odor-induced anxiety in rats: region-specific effects of the benzodiazepine midazolam. J Neurosci 24:4134-4144.
196. McKernan RM, Rosahl TW, Reynolds DS, Sur C, Wafford KA, Atack JR, Farrar S, Myers J, Cook G, Ferris P, et al. (2000) Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABA(A) receptor alpha1 subtype. Nat Neurosci 3:587-592.
197. McKernan RM and Whiting PJ (1996) Which GABAA-receptor subtypes really occur in the brain? Trends Neurosci 19:139-143.
198. McNaughton N, Kocsis B, and Hajós M (2007) Elicited hippocampal theta rhythm: a screen for anxiolytic and procognitive drugs through changes in hippocampal function? Behav Pharmacol 18:329-346.
199. McNaughton N, Swart C, Neo P, Bates V, and Glue P (2013) Anti-anxiety drugs reduce conflict-specific “theta”—a possible human anxiety-specific biomarker. J Affect Disord 148:104-111.
200. Medina JH, Paladini AC, Wolfman C, Levi de Stein M, Calvo D, Diaz LE, and Peña C (1990) Chrysin (5,7-di-OH-flavone), a naturally-occurring ligand for benzodiazepine receptors, with anticonvulsant properties. Biochem Pharmacol 40:2227-2231.
201. Medina JH, Peña C, Levi de Stein M, Wolfman C, and Paladini AC (1989) Benzodiazepine-like molecules, as well as other ligands for the brain benzodiazepine receptors, are relatively common constituents of plants. Biochem Biophys Res Commun 165:547-553.
202. Medina JH, Viola H, Wolfman C, Marder M, Wasowski C, Calvo D, and Paladini AC (1997) Overview—flavonoids: a new family of benzodiazepine receptor ligands. Neurochem Res 22:419-425.
203. Mehta AK and Shank RP (1995) Interaction of abecarnil, bretazenil, and RO 19-8022 with diazepam-sensitive and -insensitive benzodiazepine sites in the rat cerebellum and cerebral cortex. Life Sci 57:2215-2222.
204. Merikangas KR, He JP, Brody D, Fisher PW, Bourdon K, and Koretz DS (2010) Prevalence and treatment of mental disorders among US children in the 2001-2004 NHANES. Pediatrics 125:75-81.
205. Merikangas KR, Nakamura EF, and Kessler RC (2009) Epidemiology of mental disorders in children and adolescents. Dialogues Clin Neurosci 11:7-20.
206. Michael-Titus AT, Albert M, Michael GJ, Michaelis T, Watanabe T, Frahm J, Pudovkina O, van der Hart MG, Hesselink MB, Fuchs E, et al. (2008) SONU20176289, a compound combining partial dopamine D(2) receptor agonism with specific serotonin reuptake inhibitor activity, affects neuroplasticity in an animal model for depression. Eur J Pharmacol 598:43-50.
207. Mihalek RM, Banerjee PK, Korpi ER, Quinlan JJ, Firestone LL, Mi ZP, Lagenaur C, Tretter V, Sieghart W, Anagnostaras SG, et al. (1999) Attenuated sensitivity to neuroactive steroids in gamma-aminobutyrate type A receptor delta subunit knockout mice. Proc Natl Acad Sci USA 96:12905-12910.
208. Mihalek RM, Bowers BJ, Wehner JM, Kralic JE, VanDoren MJ, Morrow AL, and Homanics GE (2001) GABA(A)-receptor delta subunit knockout mice have multiple defects in behavioral responses to ethanol. Alcohol Clin Exp Res 25:1708-1718.
209. Minkeviciene R, Banerjee P, and Tanila H (2008) Cognition-enhancing and anxiolytic effects of memantine. Neuropharmacology 54:1079-1085.
210. Mirza NR, Nielsen EØ, and Troelsen KB (2007) Serotonin transporter density and anxiolytic-like effects of antidepressants in mice. Prog Neuropsychopharmacol Biol Psychiatry 31:858-866.
211. Miserendino MJ, Sananes CB, Melia KR, and Davis M (1990) Blocking of acquisition but not expression of conditioned fear-potentiated startle by NMDA antagonists in the amygdala. Nature 345:716-718.
212. Moguilevsky JA and Wuttke W (2001) Changes in the control of gonadotrophin secretion by neurotransmitters during sexual development in rats. Exp Clin Endocrinol Diabetes 109:188-195.
213. Möhler H and Okada T (1977) Benzodiazepine receptor: demonstration in the central nervous system. Science 198:849-851.
214. Morris HV, Dawson GR, Reynolds DS, Atack JR, and Stephens DN (2006) Both alpha2 and alpha3 GABAA receptor subtypes mediate the anxiolytic properties of benzodiazepine site ligands in the conditioned emotional response paradigm. Eur J Neurosci 23:2495-2504.
215. Nakamura M, Ueno S, Sano A, and Tanabe H (2000) The human serotonin transporter gene linked polymorphism (5-HTTLPR) shows ten novel allelic variants. Mol Psychiatry 5:32-38.
216. Nemeroff CB (2003) Anxiolytics: past, present, and future agents. J Clin Psychiatry 64 (Suppl 3):3-6.
217. Nichols CD, Ronesi J, Pratt W, and Sanders-Bush E (2002) Hallucinogens and Drosophila: linking serotonin receptor activation to behavior. Neuroscience 115:979-984.
218. Nichols DE and Nichols CD (2008) Serotonin receptors. Chem Rev 108:1614-1641.
219. Nielsen M, Frøkjaer S, and Braestrup C (1988) High affinity of the naturally-occurring biflavonoid, amentoflavon, to brain benzodiazepine receptors in vitro. Biochem Pharmacol 37:3285-3287.
220. Nirenberg MJ (2013) Dopamine agonist withdrawal syndrome: implications for patient care. Drugs Aging 30:587-592.
221. Noyes R Jr., DuPont RL Jr., Pecknold JC, Rifkin A, Rubin RT, Swinson RP, Ballenger JC, and Burrows GD (1988) Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. II. Patient acceptance, side effects, and safety. Arch Gen Psychiatry 45:423-428.
222. Olivier JD, Vinkers CH, and Olivier B (2013) The role of the serotonergic and GABA system in translational approaches in drug discovery for anxiety disorders. Front Pharmacol 4:74.
223. Pałucha-Poniewiera A and Pilc A (2012) Involvement of mGlu5 and NMDA receptors in the antidepressant-like effect of acamprosate in the tail suspension test. Prog Neuropsychopharmacol Biol Psychiatry 39:102-106.
224. Pape HC and Stork O (2003) Genes and mechanisms in the amygdala involved in the formation of fear memory. Ann N Y Acad Sci 985:92-105.
225. Park-Chung M, Wu FS, and Farb DH (1994) 3 alpha-Hydroxy-5 beta-pregnan-20-one sulfate: a negative modulator of the NMDA-induced current in cultured neurons. Mol Pharmacol 46:146-150.
226. Patchev VK, Shoaib M, Holsboer F, and Almeida OF (1994) The neurosteroid tetrahydroprogesterone counteracts corticotropin-releasing hormone-induced anxiety and alters the release and gene expression of corticotropin-releasing hormone in the rat hypothalamus. Neuroscience 62:265-271.
227. Pelletier JG and Paré D (2004) Role of amygdala oscillations in the consolidation of emotional memories. Biol Psychiatry 55:559-562.
228. Pesold C and Treit D (1996) The neuroanatomical specificity of the anxiolytic effects of intra-septal infusions of midazolam. Brain Res 710:161-168.
229. Phan KL, Coccaro EF, Angstadt M, Kreger KJ, Mayberg HS, Liberzon I, and Stein MB (2013) Corticolimbic brain reactivity to social signals of threat before and after sertraline treatment in generalized social phobia. Biol Psychiatry 73:329-336.
230. Phan KL, Wager TD, Taylor SF, and Liberzon I (2004) Functional neuroimaging studies of human emotions. CNS Spectr 9:258-266.
231. Phillips ML, Drevets WC, Rauch SL, and Lane R (2003) Neurobiology of emotion perception I: The neural basis of normal emotion perception. Biol Psychiatry 54:504-514.
232. Pigott TA (2003) Anxiety disorders in women. Psychiatr Clin North Am 26:621-672, vi-vii.
233. Pinna G (2010) In a mouse model relevant for post-traumatic stress disorder, selective brain steroidogenic stimulants (SBSS) improve behavioral deficits by normalizing allopregnanolone biosynthesis. Behav Pharmacol 21:438-450.
234. Pittenger C, Coric V, Banasr M, Bloch M, Krystal JH, and Sanacora G (2008) Riluzole in the treatment of mood and anxiety disorders. CNS Drugs 22:761-786.
235. Plescia F, Marino RA, Cannizzaro E, Brancato A, and Cannizzaro C (2013) The role of pregnenolone sulphate in spatial orientation-acquisition and retention: an interplay between cognitive potentiation and mood regulation. Behav Processes 99:130-137.
236. Pollack MH, Jensen JE, Simon NM, Kaufman RE, and Renshaw PF (2008) High-field MRS study of GABA, glutamate and glutamine in social anxiety disorder: response to treatment with levetiracetam. Prog Neuropsychopharmacol Biol Psychiatry 32:739-743.
237. Polter AM and Li X (2011) Glycogen Synthase Kinase-3 is an Intermediate Modulator of Serotonin Neurotransmission. Front Mol Neurosci 4:31.
238. Porcelli S, Fabbri C, and Serretti A (2012) Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with antidepressant efficacy. Eur Neuropsychopharmacol 22:239-258.
239. Pritchett DB, Lüddens H, and Seeburg PH (1989) Type I and type II GABAA-benzodiazepine receptors produced in transfected cells. Science 245:1389-1392.
240. Pritchett DB and Seeburg PH (1990) Gamma-aminobutyric acidA receptor alpha 5-subunit creates novel type II benzodiazepine receptor pharmacology. J Neurochem 54:1802-1804.
241. Pritchett DB and Seeburg PH (1991) gamma-Aminobutyric acid type A receptor point mutation increases the affinity of compounds for the benzodiazepine site. Proc Natl Acad Sci USA 88:1421-1425.
242. Purdy RH, Morrow AL, Moore PH Jr., and Paul SM (1991) Stress-induced elevations of gamma-aminobutyric acid type A receptor-active steroids in the rat brain. Proc Natl Acad Sci USA 88:4553-4557.
243. Rabow LE, Russek SJ, and Farb DH (1995) From ion currents to genomic analysis: recent advances in GABAA receptor research. Synapse 21:189-274.
244. Rando RR, Bangerter FW, and Farb DH (1981) The inactivation of gamma-aminobutyric acid transaminase in dissociated neuronal cultures from spinal cord. J Neurochem 36:985-990.
245. Rangel LM, Quinn LK, Chiba AA, Gage FH, and Aimone JB (2013) A hypothesis for temporal coding of young and mature granule cells. Front Neurosci 7:75.
246. Rasmusson AM, Pinna G, Paliwal P, Weisman D, Gottschalk C, Charney D, Krystal J, and Guidotti A (2006) Decreased cerebrospinal fluid allopregnanolone levels in women with posttraumatic stress disorder. Biol Psychiatry 60:704-713.
247. Rauch SL, Savage CR, Alpert NM, Fischman AJ, and Jenike MA (1997) The functional neuroanatomy of anxiety: a study of three disorders using positron emission tomography and symptom provocation. Biol Psychiatry 42:446-452.
248. Rauch SL, Shin LM, and Wright CI (2003) Neuroimaging studies of amygdala function in anxiety disorders. Ann N Y Acad Sci 985:389-410.
249. Ravindran LN and Stein MB (2010) The pharmacologic treatment of anxiety disorders: a review of progress. J Clin Psychiatry 71:839-854.
250. Raymond JR, Mukhin YV, Gelasco A, Turner J, Collinsworth G, Gettys TW, Grewal JS, and Garnovskaya MN (2001) Multiplicity of mechanisms of serotonin receptor signal transduction. Pharmacol Ther 92:179-212.
251. Reardon LE, Leen-Feldner EW, and Hayward C (2009) A critical review of the empirical literature on the relation between anxiety and puberty. Clin Psychol Rev 29:1-23.
252. Noebels JL, Avoli M, Rogawski MA, Olsen RW, and Delgado-Escueta AVReddy DS and Rogawski MA (2012) Neurosteroids — endogenous regulators of seizure susceptibility and role in the treatment of epilepsy, in Jasper's Basic Mechanisms of the Epilepsies (Noebels JL, Avoli M, Rogawski MA, Olsen RW, and Delgado-Escueta AV eds) 4th ed, pp 984-1002, Little, Brown and Company, Boston, MA.
253. Regier DA, Narrow WE, and Rae DS (1990) The epidemiology of anxiety disorders: the Epidemiologic Catchment Area (ECA) experience. J Psychiatr Res 24 (Suppl 2):3-14.
254. Regier DA, Rae DS, Narrow WE, Kaelber CT, and Schatzberg AF (1998) Prevalence of anxiety disorders and their comorbidity with mood and addictive disorders. Br J Psychiatry Suppl (34):24-28.
255. Reinhold JA, Mandos LA, Rickels K, and Lohoff FW (2011) Pharmacological treatment of generalized anxiety disorder. Expert Opin Pharmacother 12:2457-2467.
256. Ressler KJ and Nemeroff CB (2000) Role of serotonergic and noradrenergic systems in the pathophysiology of depression and anxiety disorders. Depress Anxiety 12 (Suppl 1):2-19.
257. Ressler KJ, Rothbaum BO, Tannenbaum L, Anderson P, Graap K, Zimand E, Hodges L, and Davis M (2004) Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear. Arch Gen Psychiatry 61:1136-1144.
258. Rhodes RA, Murthy NV, Dresner MA, Selvaraj S, Stavrakakis N, Babar S, Cowen PJ, and Grasby PM (2007) Human 5-HT transporter availability predicts amygdala reactivity in vivo. J Neurosci 27:9233-9237.
259. Rickels K and Rynn M (2002) Pharmacotherapy of generalized anxiety disorder. J Clin Psychiatry 63 (Suppl 14):9-16.
260. Roberts DS, Hu Y, Lund IV, Brooks-Kayal AR, and Russek SJ (2006) Brain-derived neurotrophic factor (BDNF)-induced synthesis of early growth response factor 3 (Egr3) controls the levels of type A GABA receptor alpha 4 subunits in hippocampal neurons. J Biol Chem 281:29431-29435.
261. Roberts DS, Raol YH, Bandyopadhyay S, Lund IV, Budreck EC, Passini MA, Wolfe JH, Brooks-Kayal AR, and Russek SJ (2005) Egr3 stimulation of GABRA4 promoter activity as a mechanism for seizure-induced up-regulation of GABA(A) receptor alpha4 subunit expression. Proc Natl Acad Sci USA 102:11894-11899.
262. Robinson RT, Drafts BC, and Fisher JL (2003) Fluoxetine increases GABA(A) receptor activity through a novel modulatory site. J Pharmacol Exp Ther 304:978-984.
263. Roozendaal B, de Quervain DJ, Ferry B, Setlow B, and McGaugh JL (2001) Basolateral amygdala-nucleus accumbens interactions in mediating glucocorticoid enhancement of memory consolidation. J Neurosci 21:2518-2525.
264. Rosso IM, Weiner MR, Crowley DJ, Silveri MM, Rauch SL, and Jensen JE (2014) Insula and anterior cingulate GABA levels in posttraumatic stress disorder: preliminary findings using magnetic resonance spectroscopy. Depress Anxiety 31:115-123.
265. Rothbaum BO, Price M, Jovanovic T, Norrholm SD, Gerardi M, Dunlop B, Davis M, Bradley B, Duncan EJ, Rizzo A, et al. (2014) A randomized, double-blind evaluation of D-cycloserine or alprazolam combined with virtual reality exposure therapy for posttraumatic stress disorder in Iraq and Afghanistan War veterans. Am J Psychiatry 171:640-648.
266. Rudolph U, Crestani F, Benke D, Brünig I, Benson JA, Fritschy JM, Martin JR, Bluethmann H, and Möhler H (1999) Benzodiazepine actions mediated by specific gamma-aminobutyric acid(A) receptor subtypes. Nature 401:796-800.
267. Rudolph U and Möhler H (2006) GABA-based therapeutic approaches: GABAA receptor subtype functions. Curr Opin Pharmacol 6:18-23.
268. Sah A, Schmuckermair C, Sartori SB, Gaburro S, Kandasamy M, Irschick R, Klimaschewski L, Landgraf R, Aigner L, and Singewald N (2012) Anxiety- rather than depression-like behavior is associated with adult neurogenesis in a female mouse model of higher trait anxiety- and comorbid depression-like behavior. Transl Psychiatr 2:e171.
269. Sah P, Faber ES, Lopez De Armentia M, and Power J (2003) The amygdaloid complex: anatomy and physiology. Physiol Rev 83:803-834.
270. Sajdyk TJ and Shekhar A (1997) Excitatory amino acid receptors in the basolateral amygdala regulate anxiety responses in the social interaction test. Brain Res 764:262-264.
271. Sandford JJ, Forshall S, Bell C, Argyropoulos S, Rich A, D’Orlando KJ, Gammans RE, and Nutt DJ (2001) Crossover trial of pagoclone and placebo in patients with DSM-IV panic disorder. J Psychopharmacol 15:205-208.
272. Schwartz TL, Siddiqui UA, and Raza S (2012) Memantine as an augmentation therapy for anxiety disorders. Case Report Psychiatry 2012:749796.
273. Schwartz TL, Siddiqui UA, Raza S, and Costello A (2010) Acamprosate calcium as augmentation therapy for anxiety disorders. Ann Pharmacother 44:1930-1932.
274. Selye H (1970) Adaptive steroids: retrospect and prospect. Perspect Biol Med 13:343-363.
275. Semeniuk T, Jhangri GS, and Le Mellédo JM (2001) Neuroactive steroid levels in patients with generalized anxiety disorder. J Neuropsychiatry Clin Neurosci 13:396-398.
276. Serra M, Ghiani CA, Motzo C, Cuccheddu T, Floris S, Giusti P, and Biggio G (1994) Imidazenil, a new partial agonist of benzodiazepine receptors, reverses the inhibitory action of isoniazid and stress on gamma-aminobutyric acidA receptor function. J Pharmacol Exp Ther 269:32-38.
277. Sertraline (2012) Prescribing information. Pfizer/Roehrig, New York.
278. Shackman AJ, Fox AS, Oler JA, Shelton SE, Davidson RJ, and Kalin NH (2013) Neural mechanisms underlying heterogeneity in the presentation of anxious temperament. Proc Natl Acad Sci USA 110:6145-6150.
279. Shen H, Gong QH, Aoki C, Yuan M, Ruderman Y, Dattilo M, Williams K, and Smith SS (2007) Reversal of neurosteroid effects at alpha4beta2delta GABAA receptors triggers anxiety at puberty. Nat Neurosci 10:469-477.
280. Sieghart W (1994) Pharmacology of benzodiazepine receptors: an update. J Psychiatry Neurosci 19:24-29.
281. Sieghart W and Sperk G (2002) Subunit composition, distribution and function of GABA(A) receptor subtypes. Curr Top Med Chem 2:795-816.
282. Sim JA, Skynner MJ, and Herbison AE (2001) Direct regulation of postnatal GnRH neurons by the progesterone derivative allopregnanolone in the mouse. Endocrinology 142:4448-4453.
283. Simpson JR, Ongür D, Akbudak E, Conturo TE, Ollinger JM, Snyder AZ, Gusnard DA, and Raichle ME (2000) The emotional modulation of cognitive processing: an fMRI study. J Cogn Neurosci 12 (Suppl 2):157-170.
284. Skolnick P, Paul SM, and Weissman BA (1984) Preclinical pharmacology of buspirone hydrochloride. Pharmacotherapy 4:308-314.
285. Smith AJ, Alder L, Silk J, Adkins C, Fletcher AE, Scales T, Kerby J, Marshall G, Wafford KA, McKernan RM, et al. (2001) Effect of alpha subunit on allosteric modulation of ion channel function in stably expressed human recombinant gamma-aminobutyric acid(A) receptors determined using (36)Cl ion flux. Mol Pharmacol 59:1108-1118.
286. Spigelman I, Li Z, Liang J, Cagetti E, Samzadeh S, Mihalek RM, Homanics GE, and Olsen RW (2003) Reduced inhibition and sensitivity to neurosteroids in hippocampus of mice lacking the GABA(A) receptor delta subunit. J Neurophysiol 90:903-910.
287. Sripada RK, Marx CE, King AP, Rampton JC, Ho SS, and Liberzon I (2013) Allopregnanolone elevations following pregnenolone administration are associated with enhanced activation of emotion regulation neurocircuits. Biol Psychiatry 73:1045-1053.
288. Staley KJ and Mody I (1992) Shunting of excitatory input to dentate gyrus granule cells by a depolarizing GABAA receptor-mediated postsynaptic conductance. J Neurophysiol 68:197-212.
289. Stein MB, Jang KL, Taylor S, Vernon PA, and Livesley WJ (2002) Genetic and environmental influences on trauma exposure and posttraumatic stress disorder symptoms: a twin study. Am J Psychiatry 159:1675-1681.
290. Stein MB, Keshaviah A, Haddad SA, Van Ameringen M, Simon NM, Pollack MH, and Smoller JW (2014) Influence of RGS2 on sertraline treatment for social anxiety disorder. Neuropsychopharmacology 39:1340-1346.
291. Stein MB, Pollack MH, Bystritsky A, Kelsey JE, and Mangano RM (2005) Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: a 6-month randomized controlled trial. Psychopharmacology (Berl) 177:280-288.
292. Steinbach JH and Akk G (2001) Modulation of GABA(A) receptor channel gating by pentobarbital. J Physiol 537:715-733.
293. Stell BM, Brickley SG, Tang CY, Farrant M, and Mody I (2003) Neuroactive steroids reduce neuronal excitability by selectively enhancing tonic inhibition mediated by delta subunit-containing GABAA receptors. Proc Natl Acad Sci USA 100:14439-14444.
294. Stephens DN, Schneider HH, Kehr W, Andrews JS, Rettig KJ, Turski L, Schmiechen R, Turner JD, Jensen LH, Petersen EN, et al. (1990) Abecarnil, a metabolically stable, anxioselective beta-carboline acting at benzodiazepine receptors. J Pharmacol Exp Ther 253:334-343.
295. Stork O, Ji FY, and Obata K (2002) Reduction of extracellular GABA in the mouse amygdala during and following confrontation with a conditioned fear stimulus. Neurosci Lett 327:138-142.
296. Stork O, Yamanaka H, Stork S, Kume N, and Obata K (2003) Altered conditioned fear behavior in glutamate decarboxylase 65 null mutant mice. Genes Brain Behav 2:65-70.
297. Strawn JR, Chu WJ, Whitsel RM, Weber WA, Norris MM, Adler CM, Eliassen JC, Phan KL, Strakowski SM, and DelBello MP (2013) A pilot study of anterior cingulate cortex neurochemistry in adolescents with generalized anxiety disorder. Neuropsychobiology 67:224-229.
298. Ströhle A, Romeo E, di Michele F, Pasini A, Hermann B, Gajewsky G, Holsboer F, and Rupprecht R (2003) Induced panic attacks shift gamma-aminobutyric acid type A receptor modulatory neuroactive steroid composition in patients with panic disorder: preliminary results. Arch Gen Psychiatry 60:161-168.
299. Swanson CJ, Bures M, Johnson MP, Linden AM, Monn JA, and Schoepp DD (2005) Metabotropic glutamate receptors as novel targets for anxiety and stress disorders. Nat Rev Drug Discov 4:131-144.
300. Toth M (2003) 5-HT1A receptor knockout mouse as a genetic model of anxiety. Eur J Pharmacol 463:177-184.
301. Tretter V, Ehya N, Fuchs K, and Sieghart W (1997) Stoichiometry and assembly of a recombinant GABAA receptor subtype. J Neurosci 17:2728-2737.
302. Tromp DP, Grupe DW, Oathes DJ, McFarlin DR, Hernandez PJ, Kral TR, Lee JE, Adams M, Alexander AL, and Nitschke JB (2012) Reduced structural connectivity of a major frontolimbic pathway in generalized anxiety disorder. Arch Gen Psychiatry 69:925-934.
303. Twyman RE, Rogers CJ, and Macdonald RL (1989) Differential regulation of gamma-aminobutyric acid receptor channels by diazepam and phenobarbital. Ann Neurol 25:213-220.
304. Tye KM, Prakash R, Kim SY, Fenno LE, Grosenick L, Zarabi H, Thompson KR, Gradinaru V, Ramakrishnan C, and Deisseroth K (2011) Amygdala circuitry mediating reversible and bidirectional control of anxiety. Nature 471:358-362.
305. Urbani A and Belluzzi O (2000) Riluzole inhibits the persistent sodium current in mammalian CNS neurons. Eur J Neurosci 12:3567-3574.
306. Uzunova V, Sheline Y, Davis JM, Rasmusson A, Uzunov DP, Costa E, and Guidotti A (1998) Increase in the cerebrospinal fluid content of neurosteroids in patients with unipolar major depression who are receiving fluoxetine or fluvoxamine. Proc Natl Acad Sci USA 95:3239-3244.
307. Van der Linden G, van Heerden B, Warwick J, Wessels C, van Kradenburg J, Zungu-Dirwayi N, and Stein DJ (2000) Functional brain imaging and pharmacotherapy in social phobia: single photon emission computed tomography before and after treatment with the selective serotonin reuptake inhibitor citalopram. Prog Neuropsychopharmacol Biol Psychiatry 24:419-438.
308. Van Laere K, Bormans G, Sanabria-Bohórquez SM, de Groot T, Dupont P, De Lepeleire I, de Hoon J, Mortelmans L, Hargreaves RJ, Atack JR, et al. (2008) In vivo characterization and dynamic receptor occupancy imaging of TPA023B, an alpha 2/alpha 3/alpha 5 subtype selective gamma-aminobutyric acid-a partial agonist. Biol Psychiatry 64:153-161.
309. Van Oekelen D, Luyten WH, and Leysen JE (2003) 5-HT2A and 5-HT2C receptors and their atypical regulation properties. Life Sci 72:2429-2449.
310. Van Oort FV, Greaves-Lord K, Verhulst FC, Ormel J, and Huizink AC (2009) The developmental course of anxiety symptoms during adolescence: the TRAILS study. J Child Psychol Psychiatry 50:1209-1217.
311. van Steveninck AL, Gieschke R, Schoemaker RC, Roncari G, Tuk B, Pieters MS, Breimer DD, and Cohen AF (1996) Pharmacokinetic and pharmacodynamic interactions of bretazenil and diazepam with alcohol. Br J Clin Pharmacol 41:565-573.
312. Varia I and Rauscher F (2002) Treatment of generalized anxiety disorder with citalopram. Int Clin Psychopharmacol 17:103-107.
313. Venlafaxine (2012) Prescribing information. Pfizer/Wyeth Pharmaceuticals, Inc., Philadelphia.
314. Villiger JW (1984) CL 218,872 binding to benzodiazepine receptors in rat spinal cord: modulation by gamma-aminobutyric acid and evidence for receptor heterogeneity. J Neurochem 43:903-905.
315. Wafford KA, Whiting PJ, and Kemp JA (1993) Differences in affinity and efficacy of benzodiazepine receptor ligands at recombinant gamma-aminobutyric acidA receptor subtypes. Mol Pharmacol 43:240-244.
316. Walker DL, Miles LA, and Davis M (2009) Selective participation of the bed nucleus of the stria terminalis and CRF in sustained anxiety-like versus phasic fear-like responses. Prog Neuropsychopharmacol Biol Psychiatry 33:1291-1308.
317. Walker DL, Ressler KJ, Lu KT, and Davis M (2002) Facilitation of conditioned fear extinction by systemic administration or intra-amygdala infusions of D-cycloserine as assessed with fear-potentiated startle in rats. J Neurosci 22:2343-2351.
318. Walker DL, Toufexis DJ, and Davis M (2003) Role of the bed nucleus of the stria terminalis versus the amygdala in fear, stress, and anxiety. Eur J Pharmacol 463:199-216.
319. Wang C, Marx CE, Morrow AL, Wilson WA, and Moore SD (2007) Neurosteroid modulation of GABAergic neurotransmission in the central amygdala: a role for NMDA receptors. Neurosci Lett 415:118-123.
320. Wang MD, Zhu D, Bäckström T, and Wahlström G (2001) The interaction between ethanol and pregnanolone at induction of anaesthesia investigated with a threshold method in male rats. Br J Pharmacol 134:1393-1402.
321. Wang SJ, Wang KY, and Wang WC (2004) Mechanisms underlying the riluzole inhibition of glutamate release from rat cerebral cortex nerve terminals (synaptosomes). Neuroscience 125:191-201.
322. Wang SM and Pae CU (2013) How much to worry about the FDA warning in the use of citalopram? Expert Rev Neurother 13:883-886.
323. Warwick JM, Carey PD, Cassimjee N, Lochner C, Hemmings S, Moolman-Smook H, Beetge E, Dupont P, and Stein DJ (2012) Dopamine transporter binding in social anxiety disorder: the effect of treatment with escitalopram. Metab Brain Dis 27:151-158.
324. Weaver CE, Land MB, Purdy RH, Richards KG, Gibbs TT, and Farb DH (2000) Geometry and charge determine pharmacological effects of steroids on N-methyl-D-aspartate receptor-induced Ca(2+) accumulation and cell death. J Pharmacol Exp Ther 293:747-754.
325. Weaver CE Jr., Marek P, Park-Chung M, Tam SW, and Farb DH (1997) Neuroprotective activity of a new class of steroidal inhibitors of the N-methyl-D-aspartate receptor. Proc Natl Acad Sci USA 94:10450-10454.
326. Whiting PJ, Bonnert TP, McKernan RM, Farrar S, Le Bourdellès B, Heavens RP, Smith DW, Hewson L, Rigby MR, Sirinathsinghji DJ, et al. (1999) Molecular and functional diversity of the expanding GABA-A receptor gene family. Ann N Y Acad Sci 868:645-653.
327. Wieland HA, Lüddens H, and Seeburg PH (1992) A single histidine in GABAA receptors is essential for benzodiazepine agonist binding. J Biol Chem 267:1426-1429.
328. Wieland S, Belluzzi J, Hawkinson JE, Hogenkamp D, Upasani R, Stein L, Wood PL, Gee KW, and Lan NC (1997) Anxiolytic and anticonvulsant activity of a synthetic neuroactive steroid Co 3-0593. Psychopharmacology (Berl) 134:46-54.
329. Williams DB and Akabas MH (2001) Evidence for distinct conformations of the two alpha 1 subunits in diazepam-bound GABA(A) receptors. Neuropharmacology 41:539-545.
330. Wingrove PB, Safo P, Wheat L, Thompson SA, Wafford KA, and Whiting PJ (2002) Mechanism of alpha-subunit selectivity of benzodiazepine pharmacology at gamma-aminobutyric acid type A receptors. Eur J Pharmacol 437:31-39.
331. Wisden W, Laurie DJ, Monyer H, and Seeburg PH (1992) The distribution of 13 GABAA receptor subunit mRNAs in the rat brain. I. Telencephalon, diencephalon, mesencephalon. J Neurosci 12:1040-1062.
332. Wolfman C, Viola H, Marder M, Wasowski C, Ardenghi P, Izquierdo I, Paladini AC, and Medina JH (1996) Anxioselective properties of 6,3′-dinitroflavone, a high-affinity benzodiazepine receptor ligand. Eur J Pharmacol 318:23-30.
333. Wolfman C, Viola H, Paladini A, Dajas F, and Medina JH (1994) Possible anxiolytic effects of chrysin, a central benzodiazepine receptor ligand isolated from Passiflora coerulea. Pharmacol Biochem Behav 47:1-4.
334. Woods AM and Bouton ME (2006) D-cycloserine facilitates extinction but does not eliminate renewal of the conditioned emotional response. Behav Neurosci 120:1159-1162.
335. Wu FS, Gibbs TT, and Farb DH (1991) Pregnenolone sulfate: a positive allosteric modulator at the N-methyl-D-aspartate receptor. Mol Pharmacol 40:333-336.
336. Wu FS, Gibbs TT, and Farb DH (1993) Dual activation of GABAA and glycine receptors by beta-alanine: inverse modulation by progesterone and 5 alpha-pregnan-3 alpha-ol-20-one. Eur J Pharmacol 246:239-246.
337. Yamawaki S (1999) The use and development of anxiolytics in Japan. Eur Neuropsychopharmacol 9 (Suppl 6):S413-S419.
338. Yang P, Jones BL, and Henderson LP (2002) Mechanisms of anabolic androgenic steroid modulation of alpha(1)beta(3)gamma(2L) GABA(A) receptors. Neuropharmacology 43:619-633.
339. Yilmazer-Hanke DM, Roskoden T, Zilles K, and Schwegler H (2003) Anxiety-related behavior and densities of glutamate, GABAA, acetylcholine and serotonin receptors in the amygdala of seven inbred mouse strains. Behav Brain Res 145:145-159.
340. Young WS 3rd, Niehoff D, Kuhar MJ, Beer B, and Lippa AS (1981) Multiple benzodiazepine receptor localization by light microscopic radiohistochemistry. J Pharmacol Exp Ther 216:425-430.
341. Zanardi R, Serretti A, Rossini D, Franchini L, Cusin C, Lattuada E, Dotoli D, and Smeraldi E (2001) Factors affecting fluvoxamine antidepressant activity: influence of pindolol and 5-HTTLPR in delusional and nondelusional depression. Biol Psychiatry 50:323-330.
342. Zwanzger P, Baghai T, Boerner RJ, Möller HJ, and Rupprecht R (2001a) Anxiolytic effects of vigabatrin in panic disorder. J Clin Psychopharmacol 21:539-540.
343. Zwanzger P, Baghai TC, Schuele C, Ströhle A, Padberg F, Kathmann N, Schwarz M, Möller HJ, and Rupprecht R (2001b) Vigabatrin decreases cholecystokinin-tetrapeptide (CCK-4) induced panic in healthy volunteers. Neuropsychopharmacology 25:699-703.
344. Zwanzger P, Eser D, Padberg F, Baghai TC, Schule C, Rötzer F, Ella R, Möller HJ, and Rupprecht R (2003) Effects of tiagabine on cholecystokinin-tetrapeptide (CCK-4)-induced anxiety in healthy volunteers. Depress Anxiety 18:140-143.
345. Zwanzger P, Zavorotnyy M, Gencheva E, Diemer J, Kugel H, Heindel W, Ruland T, Ohrmann P, Arolt V, Domschke K, et al. (2013) Acute shift in glutamate concentrations following experimentally induced panic with cholecystokinin tetrapeptide—a 3T-MRS study in healthy subjects. Neuropsychopharmacology 38:1648-1654.
346. Zweifel LS, Fadok JP, Argilli E, Garelick MG, Jones GL, Dickerson TM, Allen JM, Mizumori SJ, Bonci A, and Palmiter RD (2011) Activation of dopamine neurons is critical for aversive conditioning and prevention of generalized anxiety. Nat Neurosci 14:620-626